03 | MD Anderson Cancer Center

Single agent umbralisib effective for relapsed slow-growing...

April 01, 2019

A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment...

New potential therapeutic target for pancreatic cancer...

BY Rolaynne Kimmons

March 27, 2019

Cancer cells demand enormous amounts of molecular “food” to survive and grow, and a study published March 27 online in Nature by...

Study may explain why immunotherapy not effective for some...

BY Rolaynne Kimmons

March 25, 2019

White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune...

Study points to new strategy for boosting immunotherapy...

March 21, 2019

Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why...

MD Anderson's Making Cancer History Seminar heads to New...

BY Rolaynne Kimmons

March 19, 2019

The University of Texas MD Anderson Cancer Center presents its Making Cancer History^® Seminar, 11:30 a.m.-1:30 p.m. March 25 at the...

ZEB1 throttles therapeutic target, protecting KRAS-mutant...

BY Rolaynne Kimmons

March 13, 2019

A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas...

MD Anderson to present Making Cancer History Seminar in...

BY Rolaynne Kimmons

March 07, 2019

The University of Texas MD Anderson Cancer Center returns to Palm Beach with its Making Cancer History^® Seminar, 9-11 a.m. March 18 at...

Giulio Draetta named Chief Scientific Officer

BY Rolaynne Kimmons

March 04, 2019

The University of Texas MD Anderson Cancer Center has named Giulio Draetta, M.D., Ph. D. as chief scientific officer (CSO), a new...

Newsroom

March 2019 Archive

Single agent umbralisib effective for relapsed slow-growing...

New potential therapeutic target for pancreatic cancer...

Study may explain why immunotherapy not effective for some...

Study points to new strategy for boosting immunotherapy...

MD Anderson's Making Cancer History Seminar heads to New...

ZEB1 throttles therapeutic target, protecting KRAS-mutant...

MD Anderson to present Making Cancer History Seminar in...

Giulio Draetta named Chief Scientific Officer

Help #EndCancer

Newsroom

March 2019 Archive

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson